REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

07/03/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250307:nRSG8560Za&default-theme=true

RNS Number : 8560Z  AstraZeneca PLC  07 March 2025

7 March 2025

 

 

Transaction by Person Discharging Managerial Responsibilities

 

 

AstraZeneca PLC (the Company) announced that, on 6 March 2025, an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal
Soriot, Executive Director and Chief Executive Officer, under the terms of the
AstraZeneca Performance Share Plan (AZPSP).

 

The AZPSP award was granted on 6 March 2020 and was subject to a three-year
performance period. On the third anniversary of grant the award was placed in
a two-year holding period. The award vested at the end of that holding period.
Application of the performance measures specified at the time of grant
resulted in 97% of the AZPSP award vesting and the remaining unvested part
lapsing.

 

Following the reinvestment of dividends accrued during performance and holding
periods of the AZPSP award, and the withholding of shares to satisfy certain
tax obligations arising on vesting, Mr Soriot's beneficial interests in
Ordinary Shares changed as detailed in the table below:

 

 PDMR           Ordinary Shares acquired under the AZPSP
 Pascal Soriot  89,962

 

 

For tax purposes, the fair market value of an Ordinary Share at vest of the
AZPSP award was 12,062 pence, being the closing price on the last trading day
preceding the vesting.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Pascal Soriot

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca

                                                            Performance Share Plan, for nil consideration.

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    89,962
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      6 March 2025

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

6 March 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUBVARVRUORAR